Daily Stock Analysis, CLVS, Clovis Oncology Inc, priceseries

Clovis Oncology Inc. Daily Stock Analysis
Stock Information
Open
5.90
Close
5.95
High
6.07
Low
5.72
Previous Close
5.60
Daily Price Gain
0.35
YTD High
32.05
YTD High Date
Feb 28, 2019
YTD Low
4.98
YTD Low Date
Aug 15, 2019
YTD Price Change
-13.44
YTD Gain
-69.31%
52 Week High
37.27
52 Week High Date
Aug 22, 2018
52 Week Low
4.98
52 Week Low Date
Aug 15, 2019
52 Week Price Change
-28.80
52 Week Gain
-82.88%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 16. 2016
37.20
Jan 3. 2017
41.87
10 Trading Days
12.56%
Link
LONG
Jan 4. 2017
44.67
Feb 6. 2017
60.90
22 Trading Days
36.34%
Link
LONG
Sep 27. 2017
76.86
Oct 17. 2017
82.80
14 Trading Days
7.72%
Link
LONG
Nov 28. 2018
16.87
Dec 14. 2018
19.11
11 Trading Days
13.28%
Link
LONG
Jan 23. 2019
23.04
Feb 11. 2019
24.45
13 Trading Days
6.14%
Link
Company Information
Stock Symbol
CLVS
Exchange
NasdaqGS
Company URL
http://www.clovisoncology.com
Company Phone
(303) 625-5000
CEO
Patrick J. Mahaffy
Headquarters
Colorado
Business Address
5500 FLATIRON PARKWAY, SUITE 100, BOULDER, CO 80301
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001466301
About

Clovis Oncology, Inc. is a biopharmaceutical company which focuses on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. The company has three product candidates in its clinical development pipeline: Rociletinib, Rucaparib and Lucitani. Clovis Oncology was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Description

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. The company is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications. It distributes its product primarily through specialty distributors and pharmacy providers to patients and health care providers. The company has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and Celgene Corporation; and collaboration and license agreement with Les Laboratoires Servier. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.